Advertisement
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
William
Why is there no mention of the new antibody PRO-140 (now Leronlimab), as it will likely be approved by the FDA? Leronlemab can improve lives of most long-term HIV-positive individuals by eliminating significant side effects, reduce dosing to once/week, and eliminate harm (e.g., heart problems, etc.) that result from long-term use of HAART. The cocktail has served us well, but now it's time for a new class of treatment that is more effective and less than many others for most patients?
March 15, 2019 • New York